# Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire

> **NCT05817331** · — · COMPLETED · sponsor: **Otsuka Australia Pharmaceutical Pty Ltd** · enrollment: 16 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **OTHER:** Carer Treatment Preference Myelodysplasia Questionnaire
- **OTHER:** Clinician Treatment Preference Myelodysplasia Questionnaire
- **OTHER:** Patient Treatment Preference Myelodysplasia Questionnaire

## Key facts

- **NCT ID:** NCT05817331
- **Lead sponsor:** Otsuka Australia Pharmaceutical Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-28
- **Primary completion:** 2023-03-10
- **Final completion:** 2023-03-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817331, "Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05817331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*